Facebook
Twitter
LinkedIn
ForwardHarsh Shah, D.O.
Dr. Shah is an assistant professor in lymphoma division at HCI since 2019. His practice includes NHL, HL, and CLL. His research focuses on real-world outcomes of lymphoma patients, racial disparity and development of novel targeted agents for refractory lymphoma patients. He is a recipient of LSRMP award for a clinical trial which focuses on improving outcomes of patients with progression on anti-PD-1 agents with utilization of novel agents.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Seattle GeneticsDate added:10/01/2021Date updated:09/23/2024Relationship end date:10/19/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BeiGeneDate added:10/01/2021Date updated:09/23/2024Relationship end date:10/19/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:EpizymeDate added:02/09/2023Date updated:09/23/2024Relationship end date:02/09/2023